Deep TMS is delivered through a patented coil design which is housed within a cushioned, patient and providerfriendly helmet. By pulsing a magnetic field that targets affected structures of the brain, the Deep TMS system can stimulate important neural networks involved in mental health conditions. BrainsWay's unique therapeutic solution is currently cleared in Canada to treat major depressive disorder and obsessive-compulsive disorder. BrainsWay is a global leader in advanced noninvasive neurostimulation tr ...

BrainsWay Ltd. (BWAY) , a prominent player in noninvasive neurostimulation treatments, has initiated a clinical trial aimed at evaluating a new accelerated treatment protocol for its Deep Transcranial Magnetic Stimulation (Deep TMS) system in treating major depressive disorder (MDD). This prospective, randomized, controlled, multicenter trial represents a significant step forward in mental health treatment, particularly for those suffering from MDD. The initiation of this clinical trial underscores BrainsWa ...

About BrainsWay Investors: Brian Ritchie LifeSci Advisors britchie@lifesciadvisors.com The clinical trial is anticipated to enroll over 100 patients with major depressive disorder (MDD) who will be split into two groups – one receiving a novel accelerated treatment protocol featuring an acute phase over several treatment days, and the other receiving the FDA-cleared standard-of-care protocol which entails an acute phase over several weeks. The design of this non-inferiority trial, which was determined in di ...

Forward Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to ...

BURLINGTON, Mass. and JERUSALEM, June 03, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that the US Food and Drug Administration (FDA) has granted an expanded indication for the Company's Deep Transcranial Magnetic Stimulation system (Deep TMS™) allowing for the treatment of patients with major depressive disorder (MDD) ages 22 to 86, changing the p ...

BURLINGTON, Mass. and JERUSALEM, June 03, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that the US Food and Drug Administration (FDA) has granted an expanded indication for the Company's Deep Transcranial Magnetic Stimulation system (Deep TMS™) allowing for the treatment of patients with major depressive disorder (MDD) ages 22 to 86, changing the p ...

Shares of Brainsway Ltd. Sponsored ADR (BWAY) have gained 3.5% over the past four weeks to close the last trading session at $5.33, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $11.75 indicates a potential upside of 120.5%. While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at a ...

BrainsWay Ltd. (NASDAQ:BWAY) Q1 2024 Earnings Conference Call May 8, 2024 8:30 AM ET Troy Williams – Investor Relations, Life Science Advisors Hadar Levy – Chief Executive Officer Ido Marom – Chief Financial Officer Jeff Cohen – Ladenburg Steve Lichtman – Oppenheimer Ram Selvaraju – H.C. Wainwright Good morning, everyone. My name is Julie, and I will be your conference operator today. At this time, I would like to welcome everyone to BrainsWayÂ's First Quarter 2024 Financial Results Conference Call. All lin ...

Generated Significant 37% Year-over-Year Revenue Growth in Q1 2024 Recorded Positive Quarterly Net Income for Second Consecutive Quarter, and Positive Adjusted EBITDA and Cash Flow from Operations for Third Consecutive Quarter Conference Call to be Held Today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, May 08, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a world leader in advanced and non-invasive treatment for brain disorders, today reported first quarter ...

JERUSALEM and BURLINGTON, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced results published in a review article exploring the potential efficacy of Deep Transcranial Magnetic Stimulation (Deep TMS™) as a novel therapeutic approach for Parkinson's Disease (PD). The paper was published in Frontiers of Human Neuroscience, a leading peer-review ...